Introduction {#sec1}
============

Chronic myeloproliferative disorders (CMPD) are pluripotent hematopoietic stem cell diseases, characterized by proliferation of one or more myeloid cell lines (erythroid, granulocytic, megakaryocytic) in the bone marrow, without exhibiting any differentiation and maturation defect \[[@cit0001]\]. Common properties of these diseases include uncontrolled proliferation of one or more of the myeloid cell lines, relatively normal maturation, hepatosplenomegaly, transformation to acute leukemia in different proportions and development of bone marrow fibrosis \[[@cit0002]\]. Development, progression and myeloproliferative mechanisms of the disease are not quite clear yet. Molecular mechanisms as well as aberrant expression of the genes that regulate apoptosis are thought to play a role here too, as in other hematologic malignancies \[[@cit0003]\]. Impairment of the apoptosis mechanisms and aberrant expression of pro-antiapoptotic proteins contribute to the excessive cell proliferation and development of fibrosis \[[@cit0004]\]. The relationship between the impairment of apoptosis and various hematological malignancies (chronic neutrophilic leukemia, myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), etc.) has been revealed in the literature \[[@cit0005]\]. Apoptosis is known as programmed cell death \[[@cit0006], [@cit0007]\]. It occurs through two main mechanisms: either a change in the mitochondrial permeability (intrinsic pathway) or binding of the death receptor and the specific ligand on the cell surface (extrinsic pathway) \[[@cit0008], [@cit0009]\]. FAS (CD95) is a molecule expressed on the cell surface, and it initiates the death signal after binding to its ligand (FASL) \[[@cit0010]\]. The FAS/FASL pathway is a critical system for hematopoietic cell survival and apoptosis \[[@cit0011]--[@cit0013]\]. Genetic variations in the promoter region of FAS/FASL may play an important role in the pathogenesis of CMPD by inducing apoptosis. The aim of our study was to investigate the role of FAS/FASL gene polymorphisms in CMPD pathogenesis and their possible association with clinical parameters as well as susceptibility to the disease.

Material and methods {#sec2}
====================

Subjects {#sec2.1}
--------

One hundred and one patients with confirmed diagnosis of Philadelphia chromosome negative (Ph--) CMPD according to WHO criteria and 95 healthy volunteers were included in the study. Among 101 patients with CMPD, 34 had polycythemia vera (PV), 23 had primary myelofibrosis (PMF), and 44 had essential thrombocythemia (ET). Chronic myeloproliferative disorders patients who were regularly followed up in the hematology outpatient clinic and healthy volunteers with no history of systemic illness or systemic drug use were informed about the study in detail. The study was approved by the human research ethics committee of the hospital and informed consent was obtained from the patients and healthy volunteers who agreed to participate in the study. The patients' history, physical examination, clinical and laboratory findings (white blood count, hemoglobin, hematocrit, platelet count, iron, total iron binding capacity, ferritin, erythropoietin levels, cytogenetic and molecular examinations (Ph chromosome, Bcr-abl)) at the first diagnosis were recorded by the scanning hematology outpatient clinic follow-up program.

Molecular methods {#sec2.2}
-----------------

### Genomic DNA preparation and quantitation {#sec2.2.1}

Genomic DNA was extracted from EDTA-anticoagulated whole blood samples using a commercially available genomic DNA purification kit (Qiagen, Ontario, Canada) following the manufacturer's instructions. DNA concentration was determined spectrophotometrically by a NanoDrop digital spectrophotometer using the manufacturer's instructions and diluted as 100 ng/µl. The isolated DNA (2 µl) was loaded on 1% agarose gel to detect the quality of the DNA.

Polymerase chain reaction (PCR) amplification was carried out on a GeneAmp PCR System 9700 (PE Applied Biosystems, Foster City, CA, USA) in a 25 µl reaction mixture in 0.2 ml thin-walled PCR strip tubes (Axygen Scientific, Inc, Union City, CA, USA) containing 1 µl of genomic DNA solution, GeneAmp Gold Buffer (15 mmol/l Tris HCl, pH 8.0, 50 mmol/l KCl) (PE Applied Biosystems), 1.5 mmol MgCl~2~, 50 µmol/l each of deoxyGTP (dGTP), deoxy ATP (dATP), deoxyTTP (dTTP), and deoxyCTP (dCTP) (Promega, Madison, WI), 25 pmol each of forward and reverse primers and 1.0 U AmpliTaq Gold polymerase (PE Applied Biosystems). The cycling conditions were initially 95°C for 10 min, followed by 35 amplification cycles at 95°C for 45 s, 62°C for 45 s, and 72°C for 45 s, and a final extension at 72°C for 7 min.

### Primers used for PCR-RFLP {#sec2.2.2}

For FAS-670A\>G polymorphism the forward primer was 5′-CTA CCT AAG AGC TAT CTA CCG TTC-3′ and the reverse primer was 5′-GGC TGT CCA TGT TGT GGC TGC-3′.

### Digestion protocol {#sec2.2.3}

The amplified 331 bp PCR product (3 µl) was digested in a 10-µl final reaction volume using 1 µl of Reaction Buffer 2 and 5 units of MvaI restriction enzyme (New England Biolabs, Beverly, MA, USA) at 37°C overnight. Controls of known genotype were included for every set of digestions carried out. After digestion, allele G yielded three fragments of 99, 188, and 44 bp, whereas allele A yielded two fragments of 99 and 232 bp. Digested fragments were separated on 3% agarose gels and visualized after ethidium bromide staining in the BioDoc-It System (UVP, Upland, CA, USA) Bioimaging system.

### PCR-RFLP genotyping for --843C/T polymorphism of FASL gene {#sec2.2.4}

Genomic DNA was amplified using PCR carried out on a Gene-Amp PCR System 9700 (PE Applied Biosystems). The cycling conditions were initially 95°C for 10 min, followed by 35 amplification cycles at 95°C for 30 s, 45°C for 30 s, and 72°C for 30 s, and a final extension at 72°C for 10 min. Forward (5′-CAA TGA AAA TGA ACA CAT TG-3′) and reverse (5′-CCC ACT TTA GAA ATT AGA TC-3′) primers were used according to the published sequence (GenBank accession number AF027385).

### Digestion protocol {#sec2.2.5}

The amplified 114 bp PCR product (7 µl) was digested at 37°C for 3 h in a 20 µl final reaction volume using 2 µl of Reaction Buffer 2 and 5 units of DraIII restriction enzyme (New England Biolabs, Beverly, MA). After digestion allele T yielded two fragments of 98 and 16 bp, whereas allele C was not digested and yielded as 114 bp. Digested PCR samples were subjected to electrophoresis on gels containing a mixture of 1.5% agarose (Sigma, St. Louis, MO) and 1.5% NuSieve GTG (BMA, Rockland, ME).

### RNA isolation from peripheral blood leukocytes {#sec2.2.6}

Total RNAs were prepared from peripheral blood leukocytes (PBLs) by the Qiagen RNA Blood Mini Isolation Kit (Qiagen GmbH, Hilden, Germany). According to the manufacturer's instructions, 20 µl of the obtained total RNA was denatured for 10 min at 70°C to prevent dimerization, then reverse transcribed in a total volume of 50 µl containing 50 mM Tris HCl (pH 8.3), 75 mM KCl, 3 mM MgCl~2~, 10 mM dithiothreitol, 0.5 mM dNTPs, 15 µg/ml of random primers (Promega), 40 units of RNasin (Promega), and the RNA sample. Samples were incubated for 1 cycle in the thermal cycler for 10 min at 26°C, 60 min at 42°C, and 5 min at 95°C, and then finally cooled to 4°C. Quantity and quality assessment of the obtained cDNA molecule was evaluated by the above method. Also, conventional PCR was performed with the newly designed RT-PCR primers for confirmation of the sequences.

### FAS gene mRNA expression quantitation by real-time PCR {#sec2.2.7}

Relative quantification describes the change in expression of the target gene relative to the internal reference gene. Reactions were performed in a 50 µl volume of diluted cDNA sample, with 0.5 µM specifically designed primers (NM 000043.4), and 4 mM MgCl~2~ by the Qiagen Quantitect Probe RT-PCR kit using ABI PRISM 7000. Cycling conditions consisted of 2 min at 50°C, and 45 cycles of 10 min at 95°C, 15 s at 95°C, and 1 min at 65°C. A primer-probe set designed for human RNase P, a housekeeping gene, was added to each sample to allow normalization to the total RNA content coamplifying with FAS as an internal control.

All of the genotyping was performed blinded with respect to subject characteristics, and blinded quality control samples were inserted to validate genotypes. One sample for each of the three possible genotypes had formerly been confirmed by sequencing and served as standards in the restriction analysis. Additionally, the genotypes for FAS and FASL genes identified by the PCR restriction fragment length polymorphism (PCR-RFLP) method were confirmed by DNA sequencing, and sequences were compared with the published FAS and FASL gene DNA sequences. Concordance for blinded samples was 100%.

Statistical analysis {#sec2.3}
--------------------

The Hardy-Weinberg principle \[[@cit0014]\] was used to test whether the patient and the control groups were balanced. Then, using the *t*-test and Pearson's χ^2^ tests, the patients' and subjects' genotype distribution and allele frequency were evaluated. The association of the genotype and allele frequency with the disease parameters was assessed by χ^2^ and one-way ANOVA tests. The statistical analysis was performed using SPSS and *p* \< 0.05 was considered statistically significant.

Results {#sec3}
=======

A total of 101 CMPD patients who were diagnosed according to 2008 WHO criteria and were under the follow-up in Ege University Department of Hematology and 95 healthy volunteers (46 female/49 male, median age 49.4 years) were included in the study. Fifty of the patients were female and 51 were male, and the median age of the patients was 50.6 years. Age and gender features were homogeneous in the patient and the control groups ([Table I](#t0001){ref-type="table"}). The demographic and clinical data according to each of the three CMPD groups is shown in [Table II](#t0002){ref-type="table"}.

###### 

Demographic and clinical features of patients with CMPD and control group

  Features                          Patients (*N* = 101)   Control group (*N* = 95)
  --------------------------------- ---------------------- --------------------------
  Age (mean) \[years\]              50.6                   49.4
  Gender (F/M)                      50/51                  46/49
  Essential thrombocythemia (*N*)   44                     
  Polycythemia vera (*N*)           34                     
  Primary myelofibrosis (*N*)       23                     

###### 

Comparison of clinical and demographic features according to the three diagnoses

  Clinical and demographic features   Myelofibrosis   Essential thrombocythemia   Polycythaemia vera   
  ----------------------------------- --------------- --------------------------- -------------------- --------
  Number of patients                                  23                          44                   34
  Median age                                          55.17                       48.09                50.79
  Gender                              Male            11                          18                   22
  Female                              12              26                          12                   
  JAK2V617F mutation                  Negative        10                          31                   5
  Homozygote                          1               --                          1                    
  Heterozygote                        12              13                          28                   
  Splenomegaly                        Negative        4                           42                   10
  Positive                            19              2                           24                   
  Thrombosis                          Negative        21                          32                   22
  Positive                            2               12                          12                   
  Hepatomegaly                        Negative        13                          40                   26
  Positive                            10              4                           8                    
  Mean LDH                                            856.91                      426.22               502.32

LDH -- lactate dehydrogenase: 125--220 U/l.

FAS gene --670A\>G polymorphism {#sec3.1}
-------------------------------

When comparing FAS gene --670A\>G polymorphism genotype distribution between CMPD patients and the healthy control group, a statistically significant increase was found in AG and GG genotypes in the patient group (*p* = 0.003, [Table III](#t0003){ref-type="table"}).

###### 

Genotype distribution and allele frequency of FAS gene 670A\>G polymorphism in CMPD patients and healthy controls

  Group     Genotypes    Allele                                 
  --------- ------------ ------------ ------------ ------------ -------------
  CMPD      32 (31.7%)   54 (53.5%)   15 (14.9%)   84 (41.6%)   118 (58.4%)
  Control   52 (54.7%)   30 (31.6%)   13 (13.7%)   56 (29.5%)   134 (70.5%)

In the CMPD group, AG genotype was more prevalent, while the A allele was detected more frequently in both groups. FAS gene --670A\>G polymorphism and clinical findings such as splenomegaly and venous thrombosis showed no correlation (*p* = 0.082, *p* = 0.412, respectively) ([Table IV](#t0004){ref-type="table"}). In the comparison between ET, MF and PV groups, no significant differences were detected regarding FAS gene --670A\>G polymorphism (*p* \> 0.05) ([Figure 1](#f0001){ref-type="fig"}). Also, no statistically significant difference was found between FAS gene --670A\>G polymorphism and JAK2V617F mutation (*p* \> 0.05). FAS mRNA expression was 1.5-fold reduced in patients compared to healthy subjects and it was statistically significant (*p* = 0.003).

###### 

Clinical and laboratory findings of CMPD patients according to FAS gene --670 A\>G distribution

  Variable       AA (*N* = 32)   AG + GG (*N* = 69)   *P*-value
  -------------- --------------- -------------------- -----------
  Splenomegaly   18 (56.3%)      27 (39.1%)           0.082
  Thrombosis     10 (31.3%)      16 (23.2%)           0.412

![FAS 670 genotype distribution according to the patient disease groups: black -- essential thrombocythemia; dark gray -- myelofibrosis; light gray -- polycythemia vera](AMS-13-25681-g001){#f0001}

FASL gene 843 C/T polymorphism {#sec3.2}
------------------------------

CMPD patients and the healthy control group displayed no statistically significant differences in terms of FASL 843C\>T genotype distribution or allele frequency (*p* = 0.144) ([Table V](#t0005){ref-type="table"}). In both groups, CT genotype (46.5% and 45.3%) and the C allele (61.9% and 52.1%) were more common. FASL gene 843C\>T polymorphism and clinical findings such as splenomegaly and venous thrombosis showed no correlation (*p* \> 0.05). Moreover, no statistically significant difference was detected for FASL and JAK2V617F mutations (*p* \> 0.05). Statistical data of the correlation of FAS and FASL gene polymorphisms with clinical features in CMPD patients are shown in [Table VI](#t0006){ref-type="table"}.

###### 

Genotype distribution and allele frequency of FASL+843C\>T in CMPD patients and healthy controls

  Group                Genotypes    Allele                                  
  -------------------- ------------ ------------ ------------ ------------- ------------
  CMPD (*N* = 101)     39 (38.6%)   47 (46.5%)   15 (14.9%)   125 (61.9%)   77 (38.1%)
  Control (*N* = 95)   28 (29.5%)   43 (45.3%)   24 (25.3%)   99 (52.1%)    91 (47.9%)

###### 

Correlation of FAS/FASL gene polymorphism with clinical features in CMPD patients

  Clinical and demographic features   FAS gene --670A\>G polymorphism   FASL gene --843C\>T polymorphism   
  ----------------------------------- --------------------------------- ---------------------------------- -------------
  Gender                              Male                              *p* \> 0.05                        *p* \> 0.05
  Female                                                                                                   
  Age                                                                   *p* \> 0.05                        *p* \> 0.05
  JAK2V617F mutation                  Negative                          *p* \> 0.05                        *p* \> 0.05
  Homozygote                                                                                               
  Heterozygote                                                                                             
  Hepatomegaly                        Positive                          *p* \> 0.05                        *p* \> 0.05
  Negative                                                                                                 
  Splenomegaly                        Positive                          *p* \> 0.05                        *p* \> 0.05
  Negative                                                                                                 
  Thrombosis                          Positive                          *p* \> 0.05                        *p* \> 0.05
  Negative                                                                                                 
  Diagnosis                           Myelofibrosis                     *p* \> 0.05                        *p* \> 0.05
  Essential thrombocythemia                                                                                
  Polycythemia vera                                                                                        

Discussion {#sec4}
==========

In our study, increased Fas-670A\>G promoter polymorphism was found in the CMPD group compared to healthy controls. Also we investigated the possible relationship between Fas-670 gene polymorphism and clinical manifestations of CMPD. We did not find any correlation between the evaluated clinical findings (splenomegaly, thrombosis) and FAS gene --670A\>G polymorphism. No significant difference between CMPD and healthy control groups was found in terms of FASL gene 843C\>T genotype and allele distributions.

In addition, FASL-843 gene polymorphism showed no association with the clinical parameters of disease. Comparing the patients with the control group, Fas mRNA expression was found to be 1.5-fold decreased among the patients. Apoptosis is a biological process which maintains homeostasis. Furthermore, abnormal regulation and dysfunctioning mechanisms play an important role in the development of many hematologic and solid malignancies \[[@cit0015]\]. A possible polymorphism in the Fas/FasL gene, which has an important task in this process, can result in hematological malignancies. Tognon *et al.* included 26 ET, 12 PV and 11 PMF patients in their study examining expression of different apoptosis-related genes in patients with CMPD, and analyzed apoptotic genes, as well as the JAK2V617F mutation \[[@cit0016]\]. They detected increased expression of FAS, FASL, DR4, FAIM, and c-FLIP I in the CD34 positive cells of the CMPD group, compared with controls. Considering disease subgroups, they demonstrated increased FAS expression in PMF patients, compared to the ET group. Again, they investigated the relationship between the expression of apoptotic genes and JAK2V617F mutation and detected a positive relationship between FAS and DR5 expression and JAK2V617F mutation in patients with PV, whereas no statistically significant result was obtained in patients with ET and PMF. Zeuner *et al.* observed increased expression of FLIP in erythroid precursor cells of PV patients \[[@cit0017]\]. In the same study, they also determined the presence of the JAK2V617F mutation in PV erythroblasts. In patients with PV, resistance mechanisms against death receptor-mediated apoptosis have been claimed to have an important role in the pathogenesis of the disease. In another study supporting the effect of an impaired mechanism of apoptosis in CMPD, a balance between proliferation and apoptosis was demonstrated in patients with ET \[[@cit0018]\]. Despite precise biological and histopathological differences between ET and PMF, clinically different progression of these diseases may seem contradictory. No significant decrease was observed in overall survival of the patients with ET, whereas patients with PMF may experience a more progressive course of the disease and a poor prognosis. In recent years, bone marrow microenvironment remodeling and proliferative stress are considered to play an important role in the biology of ET and PMF. In the pathogenesis of these disorders, as a result of disruptions in apoptosis induction and regulation, decreased programmed cell death and increased proliferation can lead to clonal expansion. Only a few studies are available on platelet apoptosis and differentiation of megakaryocytes. Florena *et al.* investigated different immunophenotypic profiles in the megakaryocytes of patients with ET and PMF \[[@cit0019]\]. In the bone marrow biopsies of 30 ET and 30 PMF patients, they analyzed expression of proapoptotic (FAS, FASL, Bax, Bad) and anti-apoptotic (Bcl-2, Bcl-XL, hTERT) molecules. Increased Bcl-XL expression was detected in the megakaryocytes of patients with ET, whereas increased expression of Bax and Bad was determined in megakaryocytes of PMF. FAS/FASL expression was not detected, while the mitochondrial pathway was emphasized to be critical for megakaryocyte apoptosis in both patient groups. Based on these results, increased expression of apoptotic molecules can support the fibrotic process in PMF, while the anti-apoptotic profile seen in ET was correlated with better prognosis. The role of Fas gene polymorphisms in the pathogenesis of different hematological malignancies was reported previously. Fare *et al.* investigated the FAS gene promoter 670A\>G polymorphism in adult T-cell leukemia and compared the data with the control group, and identified AA genotypes more frequently among the patients \[[@cit0020]\]. Again, AA genotype has been associated with aggressive disease and poor prognosis, and Fas promoter polymorphism was considered to be associated with disease susceptibility, clinical signs, and survival in adult T-cell leukemia. Zhang *et al.* investigated the correlation between FAS promoter polymorphisms and cancer risk and retrospectively reviewed 11,461 cases of cancer in the electronic environment, and concluded that there was a high cancer risk related to FAS-1377 AA genotype and smoking but no relationship with FAS-670 GG genotype \[[@cit0021]\].

In conclusion, we observed significantly higher FAS-670A\>G polymorphism frequency in patients with CMPD compared with the control group. This polymorphism should be investigated in larger patient groups in terms of its role in the pathogenesis of CMPD and its susceptibility to the disease.
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